The Impact of Molecular Subtyping on Pathological Staging of Pancreatic Cancer.

Background: The long-term outcomes following surgical resection for pancreatic ductal adenocarcinoma (PDAC) remains poor, with only 20% of patients surviving 5 years after pancreatectomy. Patient selection for surgery remains suboptimal largely due to the absence of consideration of aggressive tumor biology.

Objective: The aim of this study was to evaluate traditional staging criteria for PDAC in the setting of molecular subtypes.